Literature DB >> 10188903

Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue.

C M Ferrier1, H H de Witte, H Straatman, D H van Tienoven, W L van Geloof, F J Rietveld, C G Sweep, D J Ruiter, G N van Muijen.   

Abstract

Enzyme-linked immunosorbent assay (ELISA) methods and immunohistochemistry (IHC) are techniques that provide information on protein expression in tissue samples. Both methods have been used to investigate the impact of the plasminogen activation (PA) system in cancer. In the present paper we first compared the expression levels of uPA, tPA, PAI-1 and uPAR in a compound group consisting of 33 cancer lesions of various origin (breast, lung, colon, cervix and melanoma) as quantitated by ELISA and semi-quantitated by IHC. Secondly, the same kind of comparison was performed on a group of 23 melanoma lesions and a group of 28 breast carcinoma lesions. The two techniques were applied to adjacent parts of the same frozen tissue sample, enabling the comparison of results obtained on material of almost identical composition. Spearman correlation coefficients between IHC results and ELISA results for uPA, tPA, PAI-1 and uPAR varied between 0.41 and 0.78, and were higher for the compound group and the breast cancer group than for the melanoma group. Although a higher IHC score category was always associated with an increased median ELISA value, there was an overlap of ELISA values from different scoring classes. Hence, for the individual tumour cases the relation between ELISA and IHC is ambiguous. This indicates that the two techniques are not directly interchangeable and that their value for clinical purposes may be different.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10188903      PMCID: PMC2362713          DOI: 10.1038/sj.bjc.6690245

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  25 in total

1.  Steroid receptors in breast cancer: sources of inter-laboratory variation in dextran-charcoal assays.

Authors:  S M Thorpe
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

Review 2.  The urokinase-type plasminogen activator system in cancer metastasis: a review.

Authors:  P A Andreasen; L Kjøller; L Christensen; M J Duffy
Journal:  Int J Cancer       Date:  1997-07-03       Impact factor: 7.396

3.  Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor.

Authors:  E Rønne; N Behrendt; V Ellis; M Ploug; K Danø; G Høyer-Hansen
Journal:  FEBS Lett       Date:  1991-08-19       Impact factor: 4.124

4.  The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants.

Authors:  N Behrendt; E Rønne; M Ploug; T Petri; D Løber; L S Nielsen; W D Schleuning; F Blasi; E Appella; K Danø
Journal:  J Biol Chem       Date:  1990-04-15       Impact factor: 5.157

5.  Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum.

Authors:  C F Sier; C Fellbaum; H W Verspaget; M Schmitt; G Griffioen; H Graeff; H Hôfler; C B Lamers
Journal:  Histopathology       Date:  1991-09       Impact factor: 5.087

6.  Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.

Authors:  W Kuhn; L Pache; B Schmalfeldt; P Dettmar; M Schmitt; F Jänicke; H Graeff
Journal:  Gynecol Oncol       Date:  1994-12       Impact factor: 5.482

7.  Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer.

Authors:  H E Mulcahy; M J Duffy; D Gibbons; P McCarthy; N A Parfrey; D P O'Donoghue; K Sheahan
Journal:  Lancet       Date:  1994-08-27       Impact factor: 79.321

8.  Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus.

Authors:  H Kobayashi; S Fujishiro; T Terao
Journal:  Cancer Res       Date:  1994-12-15       Impact factor: 12.701

9.  Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer.

Authors:  J A Foekens; F Buessecker; H A Peters; U Krainick; W L van Putten; M P Look; J G Klijn; M D Kramer
Journal:  Cancer Res       Date:  1995-04-01       Impact factor: 12.701

10.  Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies.

Authors:  E Rønne; G Høyer-Hansen; N Brünner; H Pedersen; F Rank; C K Osborne; G M Clark; K Danø; J Grøndahl-Hansen
Journal:  Breast Cancer Res Treat       Date:  1995-03       Impact factor: 4.872

View more
  16 in total

1.  Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.

Authors:  E Dublin; A Hanby; N K Patel; R Liebman; D Barnes
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  Protein analytical assays for diagnosing, monitoring, and choosing treatment for cancer patients.

Authors:  Alicia D Powers; Sean P Palecek
Journal:  J Healthc Eng       Date:  2012-12       Impact factor: 2.682

3.  The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas.

Authors:  Birgitte Vrou Offersen; Boye Schnack Nielsen; Gunilla Høyer-Hansen; Fritz Rank; Stephen Hamilton-Dutoit; Jens Overgaard; Peter A Andreasen
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

4.  Expression of proteinases and inhibitors in human breast cancer progression and survival.

Authors:  E A Baker; T J Stephenson; M W R Reed; N J Brown
Journal:  Mol Pathol       Date:  2002-10

5.  Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue.

Authors:  Susanne Haas; Tjoung-Won Park; Jens Claus Hahne; Hans-Peter Fischer
Journal:  Virchows Arch       Date:  2008-03       Impact factor: 4.064

6.  High tPA-expression in primary melanoma of the limb correlates with good prognosis.

Authors:  C M Ferrier; S Suciu; W L van Geloof; H Straatman; A M Eggermont; H S Koops; B B Kroon; F J Lejeune; U R Kleeberg; G N van Muijen; D J Ruiter
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

7.  Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson's disease.

Authors:  Marta Swirski; J Scott Miners; Rohan de Silva; Tammaryn Lashley; Helen Ling; Janice Holton; Tamas Revesz; Seth Love
Journal:  Alzheimers Res Ther       Date:  2014-12-01       Impact factor: 6.982

8.  High Expression of Urokinase-Type Plasminogen Activator Is Associated with Lymph Node Metastasis of Invasive Ductal Carcinoma of the Breast.

Authors:  Eun Young Kim; Sung-Im Do; Keehoon Hyun; Yong Lai Park; Dong-Hoon Kim; Seoung Wan Chae; Jin Hee Sohn; Chan Heun Park
Journal:  J Breast Cancer       Date:  2016-06-24       Impact factor: 3.588

9.  Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues.

Authors:  Thomas D Pfister; Melinda Hollingshead; Robert J Kinders; Yiping Zhang; Yvonne A Evrard; Jiuping Ji; Sonny A Khin; Suzanne Borgel; Howard Stotler; John Carter; Raymond Divelbiss; Shivaani Kummar; Yves Pommier; Ralph E Parchment; Joseph E Tomaszewski; James H Doroshow
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

10.  An ultra-sensitive immunoassay for quantifying biomarkers in breast tumor tissue.

Authors:  Carol B Fowler; Yan-Gao Man; Jeffrey T Mason
Journal:  J Cancer       Date:  2014-01-05       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.